Physician profile
Jon Meyerle
NPI 1972552545
$1,596.85
in general payments reported to CMS, 2019-2025
20 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $384 · 2021: $339 · 2022: $317 · 2023: $143 · 2024: $20.74 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $289.20 | 2020-2025 | Tremfya |
| Abbvie INC. | $273.17 | 2019-2024 | |
| Genzyme Corporation | $195.37 | 2019-2023 | |
| Leo Pharma INC. | $146.88 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $115.06 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $86.47 | 2019-2020 | |
| Ucb, INC. | $83.13 | 2019-2022 | |
| Incyte Corporation | $80.57 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $53.51 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.71 | 2019-2020 | |
| Dermira, INC. | $35.74 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $30.21 | 2021-2023 | Libtayo |
| Pfizer INC. | $29.24 | 2020-2021 | |
| Genentech USA, INC. | $22.97 | 2023 | Xolair |
| Dermavant Sciences, INC. | $20.85 | 2023 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $19.81 | 2020 | |
| Galderma Laboratories, L.P. | $18.43 | 2023 | |
| Lilly USA, LLC | $16.69 | 2019 | |
| Mission Pharmacal Company | $14.96 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Meyerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.